Dotmatics Streamlines Workflow for Antibody Research
Dotmatics has launched its Biology Solution for Antibody Discovery, a cloud-based, end-to-end software platform that integrates with popular scientific tools like Geneious, SnapGene, and GraphPad Prism to centralize data management, automate workflows, reduce errors, and accelerate antibody research amid a rapidly growing antibody therapy market projected to reach up to $700 billion by 2032.
Dotmatics has announced the release of its Biology Solution for Antibody Discovery, an end-to-end software and data management package designed to streamline data collection and workflows in antibody research. This solution integrates Dotmatics’ enterprise scientific platform with widely used applications in antibody discovery laboratories, such as Geneious, SnapGene, and GraphPad Prism. The integration aims to facilitate more effective and efficient discovery processes, accelerating the development of potentially life-changing therapies.
According to Mike McKee, president of Dotmatics, this launch represents the industry’s first comprehensive solution for antibody workflows, helping scientists harmonize data science with scientific data across R&D for biology, chemistry, and formulations.
A major challenge in drug discovery is the fragmentation of research data across siloed enterprise and local systems, which forces scientists to choose between speed and accuracy. Disconnected workflows often result in manual data handling, increasing the risk of errors and inefficiencies. The Dotmatics antibody workflow addresses these issues by providing a cloud-based, centralized data management platform fully integrated with trusted scientific applications and productivity tools. This automation of manual, error-prone tasks and centralization of data management enables organizations to make smarter decisions and accelerate antibody research.
The antibody therapy market is projected to experience significant growth, with estimates suggesting it will reach $700 billion by 2032, up from $186 billion, according to a 2022 report by Future Market Insights. Another report by the Insight Partners projects the global monoclonal antibody market will reach $243 billion by 2028, up from $111 billion in 2021.
Michael Swartz, senior vice president of enterprise product at Dotmatics, emphasized the company’s role in connecting scientists with their data to accelerate innovation and improve global health. Dotmatics is focused on providing end-to-end solutions with connected data and workflows, allowing researchers to use familiar tools while centralizing data to meet organizational needs.
The Dotmatics antibody workflow incorporates FAIR data practices and offers a comprehensive solution that spans early candidate selection through cycles of innovation, ultimately providing refined antibody candidates for animal trials and translational medicine.
About Dotmatics
Dotmatics is a leader in R&D scientific software, connecting science, data, and decision-making. Its enterprise R&D platform and popular scientific applications drive efficiency and accelerate innovation. Dotmatics serves more than 2 million scientists and 10,000 customers worldwide, with a global team of over 800 employees and offices in more than 14 locations. The company is backed by Insight Partners, a leading global venture capital and private equity firm investing in high-growth technology and software companies.
Related
Assay Screening Software Solution
The Dotmatics assay screening software solution offers an efficient data management policy that prevents data loss, automates accurate and rapid test article reporting, ensures secure real-time data sharing for CROs with flexible hosting options, and streamlines discovery through open data access, advanced visualization, and compatibility with complex workflows.
Simplify your laboratory workflow management with Dotmatics
Dotmatics offers a unified scientific R&D platform that streamlines laboratory workflow management by integrating various scientific applications, automating data extraction, cleaning, and harmonization into FAIR formats, thereby reducing manual data handling, enhancing collaboration, and accelerating the R&D cycle to help life sciences organizations bring new therapies to market faster.
Dotmatics Scientific R&D Platform Introduces Built-in GraphPad Prism Integrations
Dotmatics has integrated its cloud-based scientific R&D platform with GraphPad Prism, enabling researchers to directly export large assay datasets using customizable Prism templates for standardized, no-code, reproducible analyses and publication-quality graphs, thereby accelerating drug discovery by saving time, improving data quality, and supporting FAIR data principles.
Biologics Drug Discovery
The Dotmatics Biology Solution offers comprehensive end-to-end data management and analysis tools tailored for biologics drug discovery—including antibodies, CAR-T cells, and RNA therapeutics—facilitating collaborative workflows in molecular cloning, protein production, biologics registration, and assay data analysis to accelerate innovation and streamline complex research processes.
Joining Forces with Insightful Science
Dotmatics and Insightful Science have merged to form the world’s largest cloud-based scientific research R&D platform, combining their software solutions to accelerate innovation, enhance data-driven research workflows, and drive the digital transformation of scientific labs into the Lab of the Future.
Discover Dotmatics - San Francisco
Dotmatics is hosting a networking event on March 21, 2024, at The Anecdote in South San Francisco featuring their leaders who will present the Dotmatics Luma R&D data management tool, discuss the new GraphPad Prism integration to accelerate research, and explore digital transformation strategies in science, all while providing opportunities for peer connection and industry insights.